MedTrace Logo

High - Flow Nasal Cannula Versus Conventional Nasal Cannula During Endobronchial Ultrasound Procedure

NCT06637280 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-10-15

No results posted yet for this study

Summary

EBUS bronchoscopy is performed in most centers under local anesthesia and moderate sedation. Both the bronchoscopy itself and the sedation can lead to decreased ventilation and a drop in oxygen saturation in the body. Typically, oxygen is administered during the procedure via a nasal cannula at a flow rate of 6l/min. The aim of the study is to compare a new method - a nasal cannula with high flow - to the standard cannula. The primary objective is to demonstrate that the new method is more effective at preventing desaturation during the procedure. Patients will be randomized into two groups before bronchoscopy and monitored. The bronchoscopy will be performed in the same way for both groups. The only difference between the groups will be in the method of oxygen administration during EBUS bronchoscopy.

Conditions

  • Hypoxemia During EBUS Bronchoscopy

Interventions

DEVICE

High - flow nasal cannula

High flow nasal cannula (HFNC), a device first introduced in neonates and pediatric care, is currently used in a wide range of indications in adult respiratory and critical care medicine (5-7). It is a relatively new method in bronchoscopy with several notable theoretical advantages over low flow oxygen via conventional nasal cannula (CNC): * High flow up to 60 liters per minute ensures a more stable FiO2 and better matches the increased patient's inspiratory flow * High flow generates a small positive expiratory airway pressure (up to 5 cm H2O) which could stabilize the upper airways during sedation and have a beneficial effect in the lower airways * High flow reduces dead space in the upper airways and increases alveolar ventilation.

DEVICE

Standard nasal cannula

Standard method for supplementing oxygen during EBUS bronchoscopy

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    collaborator OTHER

  • Clinical Hospital Centre Zagreb

    collaborator OTHER

  • Universidade Nova de Lisboa

    collaborator OTHER

  • The University Clinic of Pulmonary and Allergic Diseases Golnik

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • Croatia
  • Greece
  • Portugal
  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06637280 on ClinicalTrials.gov